Your session is about to expire
← Back to Search
Pembrolizumab + Cryoablation for Mesothelioma
Study Summary
This trial is testing whether a combination of two cancer treatments is safe and effective for people with mesothelioma.
Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2024 Phase 2 trial • 57 Patients • NCT03004183Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
What potential risks are associated with Pembrolizumab treatment?
"Our team at Power rated the safety of Pembrolizumab as a 1, given that it is in its initial testing phase with limited evidence backing up the efficacy and security of this medication."
What medical conditions is Pembrolizumab commonly utilized to address?
"Pembrolizumab is often prescribed to treat cancerous neoplasms, as well as unresectable melanomas, microsatellite instability high and further progression of the disease after chemotherapy."
Are there numerous facilities within this state executing the trial?
"This trial is currently accepting patients from 7 different medical centres, including those in Commack, Uniondale and New york as well as 4 other locations. To minimize the burden of travel during enrolment, individuals should select a site situated closest to them."
Is enrollment for this trial still underway?
"Affirmative. The details hosted on clinicaltrials.gov assert that enrollment for this medical trial is ongoing, having been initially posted in September 2021 and last updated in June 2022. This research necessitates the recruitment of 10 individuals from 7 different sites."
Are there any precedent studies that have employed Pembrolizumab?
"Pembrolizumab was first researched in 2010 at City of Hope, and since then there have been 251 completed studies. Presently, the drug is being tested in 961 active trials, with a particular focus on Commack, New york."
How many individuals can participate in this investigation?
"Affirmative, the information available on clinicaltrials.gov implies that this trial is actively searching for participants. This study was initially posted in September 2021 and has been recently modified in June 2022; 10 individuals are required to be recruited from 7 medical centres."
Share this study with friends
Copy Link
Messenger